Literature DB >> 12749007

Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children.

Rogelio Paredes-Aguilera1, Lina Romero-Guzman, Norma Lopez-Santiago, Rosa Arana Trejo.   

Abstract

To assess the incidence, clinical features at presentation, hematologic, immunophenotypic, and cytogenetic characteristics of AMKL in children we prospectively studied 834 consecutive non selected children with newly diagnosed acute leukemia (AL) admitted to the Hematology Department at the Instituto Nacional de Pediatría (INP), Mexico, D.F. We found 682 cases (81.8%) with a typical ALL immunophenotype, and the remaining 152 (18.2%) were considered to have AML. In 29 of the 152 patients with AML studied, a diagnosis of AMKL was established. These 29 cases represented 19.1% of the cases of AML and 3.48% of the total cases of AL during the time span covered by the study. Twenty-four percent of the cases occurred in infants 2 years old or younger and 41.4% occurred in children 41 months of age or younger. In contrast, in only 18.6% of the patients with AML (M0-M6), the diagnosis was established before 42 months of age and in 17% before their second year of life. Clinical presentation was not strikingly different than that observed in patients with other types of AML, and the time interval from onset of symptoms to diagnosis was also similar, though in a small subset of patients, the clinical course was characterized by a chronic slowly progressive disorder extending over weeks or months resembling smoldering leukemia or chronic myelofibrosis with agnogenic myeloid metaplasia. Bone marrow (BM) fibrosis was a constant features in our patients; 75% of the patients studied showed this complication at the time of diagnosis. Some rather unusual findings in this study were intense skeletal pains from multiple osteolytic lesions, the presence of soft-tissue tumor, and the presence of cohesive scanty clusters of primitive-looking blast cells in BM aspirates. Several interesting cytogenetic findings in our study were t(1;22)(p13;q13) in a 14-year-old boy, t(9;22)(q34;q11) in one patient, and monosomy 7 in two patients. Another important finding in our study was the clinical association with colonic adenocarcinoma in one patient, an association that to our knowledge has not been reported previously. In conclusion, our data suggest that the incidence of AMKL in Mexico might be higher than those reported in Caucasian white pediatric population, and that biologic and cytogenetic profile may differ from those of western countries, but more studies are needed to corroborate cytogenetic heterogeneity, ethnic and geographic diversity. Early onset of the disease, low WBC counts, slight thrombocytopenia or normal platelet counts, and BM fibrosis were characteristic distinctive features of at least half of the patients with this subtype of AML. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12749007     DOI: 10.1002/ajh.10320

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

1.  JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.

Authors:  Thomas Mercher; Gerlinde Wernig; Sandra A Moore; Ross L Levine; Ting-Lei Gu; Stefan Fröhling; Dana Cullen; Roberto D Polakiewicz; Olivier A Bernard; Titus J Boggon; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

2.  Constitutional chromosomal abnormality identified in a sibling donor after bone marrow stem cell transplantation in a pediatric patient with acute megakaryoblastic leukemia.

Authors:  Bo-Young Seo; Hyun-Woo Choi; Min-Gu Kang; Duck Cho; Seung-Jung Kee; Soo-Hyun Kim; Jong-Hee Shin; Soon-Pal Suh; Dong-Wook Ryang; Myung-Geun Shin
Journal:  Ann Lab Med       Date:  2014-12-08       Impact factor: 3.464

3.  The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model.

Authors:  Thomas Mercher; Glen D Raffel; Sandra A Moore; Melanie G Cornejo; Dominique Baudry-Bluteau; Nicolas Cagnard; Jonathan L Jesneck; Yana Pikman; Dana Cullen; Ifor R Williams; Koichi Akashi; Hirokazu Shigematsu; Jean-Pierre Bourquin; Marco Giovannini; William Vainchenker; Ross L Levine; Benjamin H Lee; Olivier A Bernard; D Gary Gilliland
Journal:  J Clin Invest       Date:  2009-03-16       Impact factor: 14.808

4.  RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia.

Authors:  Holly Edwards; Chengzhi Xie; Katherine M LaFiura; Alan A Dombkowski; Steven A Buck; Julie L Boerner; Jeffrey W Taub; Larry H Matherly; Yubin Ge
Journal:  Blood       Date:  2009-07-28       Impact factor: 22.113

5.  Gene profiling of the erythro- and megakaryoblastic leukaemias induced by the Graffi murine retrovirus.

Authors:  Veronique Voisin; Philippe Legault; Diana Paulina Salazar Ospina; Yaacov Ben-David; Eric Rassart
Journal:  BMC Med Genomics       Date:  2010-01-26       Impact factor: 3.063

6.  Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models.

Authors:  Clarisse Thiollier; Cécile K Lopez; Bastien Gerby; Cathy Ignacimouttou; Sandrine Poglio; Yannis Duffourd; Justine Guégan; Paola Rivera-Munoz; Olivier Bluteau; Vinciane Mabialah; M'boyba Diop; Qiang Wen; Arnaud Petit; Anne-Laure Bauchet; Dirk Reinhardt; Beat Bornhauser; Daniel Gautheret; Yann Lecluse; Judith Landman-Parker; Isabelle Radford; William Vainchenker; Nicole Dastugue; Stéphane de Botton; Philippe Dessen; Jean-Pierre Bourquin; John D Crispino; Paola Ballerini; Olivier A Bernard; Françoise Pflumio; Thomas Mercher
Journal:  J Exp Med       Date:  2012-10-08       Impact factor: 14.307

7.  Rbm15-Mkl1 interacts with the Setd1b histone H3-Lys4 methyltransferase via a SPOC domain that is required for cytokine-independent proliferation.

Authors:  Jeong-Heon Lee; David G Skalnik
Journal:  PLoS One       Date:  2012-08-21       Impact factor: 3.240

8.  Alpha-Synuclein Expression in Acute Erythroleukaemia, Acute Megakaryoblastic Leukemia, and Normal Counterparts in Bone Marrow.

Authors:  Farid Kosari; Sanam Akbarzadeh Hosseini; Hiva Saffar
Journal:  Iran J Pathol       Date:  2016-08-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.